ADHD Therapeutics Market Research Report - Global Forecast till 2025

ADHD Therapeutics Market Scenario

ADHD Therapeutics Market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 19.7 billion in 2018 and is projected to register a 6.8% CAGR over the forecast period.

Attention-Deficit/Hyperactivity Disorder (ADHD) is a brain disorder, in which there is an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. Factors such as the rising prevalence of ADHD, rising use of additives & preservatives in children’s diet and increasing awareness regarding ADHD are expected to propel the growth of the market.

The existence of comorbid conditions in children leads to underdiagnoses of ADHD. This factor hampers the market growth during the forecast period. Moreover, limited availability of non-stimulant drugs is expected to adversely affect the market.

ADHD Therapeutics Market Segmentation

The global ADHD therapeutics market has been segmented into drug type, age-group, end-user, and region.

Based on drug type, the global ADHD therapeutics market has been divided into stimulants and non-stimulants. The stimulants segment further sub-segmented into amphetamine, methylphenidate, dextroamphetamine, dexamphetamine, lisdexamfetamine, and others. The lisdexamfetamine sub-segment is expected to be the largest segment owing to the high preference of the drug by doctors. Non-stimulants are further segmented into atomoxetine, bupropion, guanfacine, and clonidine.

The global ADHD therapeutics market, by treatment, has been bifurcated into pediatric & adolescents and adults.

The global ADHD therapeutics market, by end user, has been bifurcated into specialty clinics, hospitals & clinics, and others.

The ADHD Therapeutics Market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ADHD therapeutics market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European ADHD therapeutics market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.

The ADHD therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The Middle East & Africa ADHD therapeutics market is segmented into the Middle East and Africa.

ADHD Therapeutics Market Key Players
Advanz Pharmaceutical (Canada), Eli Lilly and Company (US), Highland Therapeutics Inc. (Canada), Janssen Pharmaceuticals, Inc. (Belgium), NEOS Therapeutics, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Noven Pharmaceuticals, Inc. (US), Shire (US), Teva Pharmaceutical Industries Ltd. (Israel), Impax Laboratories, LLC (US), GlaxoSmithKline plc (UK) and Purdue Pharma L.P. (US) are some of the key players operating in the global ADHD therapeutics market.

**ADHD Therapeutics Regional Market Summary**

**Global ADHD Therapeutics Market Share (%), by Region, 2018**

![Market Share Chart](chart)

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports

Geographically, the ADHD Therapeutics Market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is anticipated to dominate the ADHD therapeutics market due to its well-developed healthcare infrastructure, rising prevalence of ADHD, and early approvals for therapeutics in the region. According to data published by the Centers for Disease Control and Prevention, till 2016, a total of 6.1 million children in the US had ADHD.

Europe is expected to hold the second-largest share of the ADHD therapeutics market owing to government support and improving healthcare-related research and development.

The ADHD therapeutics market in Asia-Pacific comprises China, Japan, South Korea, India, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to be the fastest-growing region in the market, owing to the increasing prevalence of ADHD and rising healthcare spending. According to a report published by the National Center for Biotechnology Information in January 2017, 6.26% of children and adolescents in China had ADHD.

The Middle East & Africa is expected to hold the least share of the market during the forecast period. The market growth in this region is expected to be driven by the development of healthcare infrastructure.

**Global ADHD Therapeutics Market, by Drug Type**

- **Stimulants**
  - Amphetamine
  - Methylphenidate
  - Dextroamphetamine
  - Dexmethylphenidate
  - Lisdexamfetamine
  - Other
- **Non-Stimulants**
  - Atomoxetine
  - Bupropion
  - Guanfacine
Clonidine

Global ADHD Therapeutics Market, by Age Group
- Pediatric and Adolescents
- Adults

Global ADHD Therapeutics Market, by End User
- Specialty Clinics
- Hospital Pharmacies
- Retail Pharmacies
- Others

Global ADHD Therapeutics Market, by Region
- Americas
  - North America
    - US
    - Canada
  - Latin America
- Europe
  - Western Europe
    - Germany
    - France
    - Italy
    - Spain
    - UK
    - Rest of Western Europe
  - Eastern Europe
- Asia-Pacific
  - Japan
  - China
  - India
  - Australia
  - South Korea
  - Rest of Asia-Pacific
- Middle East & Africa
  - Middle East
  - Africa

ADHD Therapeutics Market Intended Audience
- Pharmaceutical companies
- Contract research organizations
- Contract manufacturing organizations
- Research and development organization
- Academics and research institutes

Contents:

Table of Contents

1. ADHD THERAPEUTICS MARKET REPORT PROLOGUE
2. ADHD THERAPEUTICS MARKET INTRODUCTION
   2.1. Definition
   2.2. Scope of the Study
   2.2.1. Research Objective
   2.2.2. Assumptions
   2.2.3. Limitations
3. ADHD THERAPEUTICS MARKET RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation

4. ADHD THERAPEUTICS MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. ADHD THERAPEUTICS MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis

6. GLOBAL ADHD THERAPEUTICS MARKET, BY DRUG TYPE
6.1. Overview
6.2. Stimulants
   Market Estimates & Forecast, by Region, 2019–2025
   6.2.1. Amphetamine
   Market Estimates & Forecast, by Region, 2019–2025
   6.2.2. Methylphenidate
   Market Estimates & Forecast, by Region, 2019–2025
   6.2.3. Dextroamphetamines
   Market Estimates & Forecast, by Region, 2019–2025
   6.2.4. Dexamphetamine
   Market Estimates & Forecast, by Region, 2019–2025
   6.2.5. Lisidexametamine
   Market Estimates & Forecast, by Region, 2019–2025
   6.2.6. Others
   Market Estimates & Forecast, by Region, 2019–2025
6.3. Non-Stimulants
   Market Estimates & Forecast, by Region, 2019–2025
   6.3.1. Atomoxetine
   Market Estimates & Forecast, by Region, 2019–2025
   6.3.2. Bupropion
Market Estimates & Forecast, by Region, 2019–2025

6.3.3. Guanfacine
Market Estimates & Forecast, by Region, 2019–2025

6.3.4. Clonidine
Market Estimates & Forecast, by Region, 2019–2025

7. GLOBAL ADHD THERAPEUTICS MARKET, BY AGE GROUP

7.1. Overview

7.2. Pediatric and Adolescent
Market Estimates & Forecast, by Region, 2019–2025

7.3. Adults
Market Estimates & Forecast, by Region, 2019–2025

8. GLOBAL ADHD THERAPEUTICS MARKET, BY END USER

8.1. Overview

8.2. Specialty Clinics
Market Estimates & Forecast, by Region, 2019–2025

8.3. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2019–2025

8.4. Others
Market Estimates & Forecast, by Region, 2019–2025

9. GLOBAL ADHD THERAPEUTICS MARKET, BY REGION

9.1. Overview

9.2. AmericasADHD Therapeutics Market
9.2.1. North America
9.2.1.1. US

9.2.1.2. Canada
9.2.2. Latin America

9.3. EuropeADHD Therapeutics Market
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe

9.4. Asia-PacificADHD Therapeutics Market
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa ADHD Therapeutics Market
9.5.1. Middle East
9.5.2. Africa
10. ADHD THERAPEUTICS MARKET COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global ADHD Therapeutics Market
10.5. Competitive Benchmarking
10.6. Leading Players in terms of Number of Developments in the Global ADHD Therapeutics Market
10.7. Key developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8.1. Sales & Operating Income 2018
10.8.2. Major Players R&D Expenditure 2018
10.9. Major Players Capital Market Ratio
11. ADHD THERAPEUTICS MARKET COMPANY PROFILES
11.1. Advanz Pharmaceutical
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Eli Lilly and Company
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Highland Therapeutics Inc.
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Janssen Pharmaceuticals, Inc.
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. GlaxoSmithKline plc
11.12.1. Company Overview
11.12.2. Product Overview
11.12.3. Financial Overview
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Purdue Pharma L.P.
11.13.1. Company Overview
11.13.2. Product Overview
11.13.3. Financial Overview
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. Others

12. APPENDIX
12.1. References
12.2. Related Reports

LIST OF TABLES
TABLE 1 GLOBAL ADHD THERAPEUTICS MARKET SYNOPSIS, 2019–2025
TABLE 2 GLOBAL ADHD THERAPEUTICS MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)
TABLE 3 GLOBAL ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 4 GLOBAL ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 5 GLOBAL ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 6 GLOBAL ADHD THERAPEUTICS MARKET, BY REGION, 2019–2025 (USD MILLION)
TABLE 7 NORTH AMERICA: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 8 NORTH AMERICA: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 9 NORTH AMERICA: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 10 US: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 11 US: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 12 US: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 13 CANADA: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 14 CANADA: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 15 CANADA: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 16 LATIN AMERICA: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 17 LATIN AMERICA: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 18 LATIN AMERICA: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 19 EUROPE: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 20 EUROPE: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 21 EUROPE: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 22 WESTERN EUROPE: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 23 WESTERN EUROPE: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 24 WESTERN EUROPE: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 25 EASTERN EUROPE: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 26 EASTERN EUROPE: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 27 EASTERN EUROPE: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 28 ASIA-PACIFIC: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 29 ASIA-PACIFIC: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 30 ASIA-PACIFIC: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: ADHD THERAPEUTICS MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: ADHD THERAPEUTICS MARKET, BY AGE GROUP, 2019–2025 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: ADHD THERAPEUTICS MARKET, BY END USER, 2019–2025 (USD MILLION)

LIST OF FIGURES
FIGURE 1 ADHD THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ADHD THERAPEUTICS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ADHD THERAPEUTICS MARKET
FIGURE 4 GLOBAL ADHD THERAPEUTICS MARKET SHARE, BY DRUG TYPE, 2018 (%)
FIGURE 5 GLOBAL ADHD THERAPEUTICS MARKET SHARE, BY AGE GROUP, 2018 (%)
FIGURE 6 GLOBAL ADHD THERAPEUTICS MARKET SHARE, BY END USER, 2018 (%)
FIGURE 7 GLOBAL ADHD THERAPEUTICS MARKET SHARE, BY REGION, 2018 (%)
FIGURE 7 AMERICAS: ADHD THERAPEUTICS MARKET SHARE BY REGION, 2018 (%)
FIGURE 8 NORTH AMERICA: ADHD THERAPEUTICS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 9 EUROPE: ADHD THERAPEUTICS MARKET SHARE, BY REGION, 2018 (%)
FIGURE 10 WESTERN EUROPE: ADHD THERAPEUTICS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 11 ASIA-PACIFIC: ADHD THERAPEUTICS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 12 MIDDLE EAST & AFRICA: ADHD THERAPEUTICS MARKET SHARE, BY COUNTRY, 2018 (%)
FIGURE 13 GLOBAL ADHD THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2018 (%)
FIGURE 14 ADVANZ PHARMACEUTICAL.: KEY FINANCIALS
FIGURE 15 ADVANZ PHARMACEUTICAL: SEGMENTAL REVENUE
FIGURE 16 ADVANZ PHARMACEUTICAL: REGIONAL REVENUE
FIGURE 17 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 18 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 19 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 20 HIGHLAND THERAPEUTICS INC.: KEY FINANCIALS
FIGURE 21 HIGHLAND THERAPEUTICS INC.: SEGMENTAL REVENUE
FIGURE 22 HIGHLAND THERAPEUTICS INC.: REGIONAL REVENUE
FIGURE 23 JANSSEN PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 24 JANSSEN PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 25 JANSSEN PHARMACEUTICALS, INC.: REGIONAL REVENUE
FIGURE 26 NEOS THERAPEUTICS, INC.: KEY FINANCIALS
FIGURE 27 NEOS THERAPEUTICS, INC.: SEGMENTAL REVENUE
FIGURE 28 NEOS THERAPEUTICS, INC.: REGIONAL REVENUE
FIGURE 29 PFIZER INC.: KEY FINANCIALS
FIGURE 30 PFIZER INC.: SEGMENTAL REVENUE
FIGURE 31 PFIZER INC.: REGIONAL REVENUE
FIGURE 32 NOVARTIS AG: KEY FINANCIALS
FIGURE 33 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 34 NOVARTIS AG: REGIONAL REVENUE
FIGURE 35 NOVEN PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 36 NOVEN PHARMACEUTICALS, INC.: SEGMENTAL REVENUE